Menu
Lausanne, Switzerland, and Boston, United States, April 8, 2020: SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Lara Hashimoto has joined its Executive Team as Chief Business Officer, effective April 1st. She will be responsible for Marketing, Product Management and Business Development.
Lara Hashimoto joined the healthcare industry 20 years ago holding several leadership roles spanning Pharma clinical drug development, sales and marketing before moving to Roche Diagnostics. Here, she held a number of roles responsible for IVD development and commercialization, including the launch of the Oncology companion diagnostics portfolio. Her most recent position before joining SOPHiA GENETICS was Chief Commercial Officer for Roche Sequencing Solutions.
“Lara is a stellar addition to our successful team. She shares the company’s vision regarding multi-modal data approaches and the optimization of drug development and has made it her mission to help improve patients’ lives. Lara will greatly further our efforts to democratize Data-Driven Medicine worldwide,” said Jurgi Camblong, Founder and CEO of SOPHiA GENETICS.
“I believe the future in healthcare will be increasingly individualized with significantly improved outcomes through the application of multi-modality prediction modelling,” said Hashimoto. “SOPHiA GENETICS is best positioned to drive this transformation.”
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
